AADI Aadi Bioscience, Inc. Stock Quote

AADI [NASD]

Index	-	P/E	-	EPS (ttm)	-11.45	Insider Own	13.54%	Shs Outstand	20.97M	Perf Week	0.69%
Market Cap	276.95M	Forward P/E	-	EPS next Y	-2.78	Insider Trans	-0.12%	Shs Float	18.17M	Perf Month	-8.09%
Income	-135.20M	PEG	-	EPS next Q	-0.74	Inst Own	64.80%	Short Float	3.52%	Perf Quarter	-13.33%
Sales	6.70M	P/S	41.34	EPS this Y	-712.40%	Inst Trans	4.70%	Short Ratio	4.19	Perf Half Y	-26.82%
Book/sh	5.18	P/B	2.52	EPS next Y	7.60%	ROA	-90.50%	Target Price	43.50	Perf Year	-50.64%
Cash/sh	5.60	P/C	2.33	EPS next 5Y	-	ROE	-103.90%	52W Range	11.00 - 32.99	Perf YTD	-45.88%
Dividend	-	P/FCF	-	EPS past 5Y	-1.30%	ROI	-77.90%	52W High	-60.32%	Beta	1.45
Dividend %	-	Quick Ratio	9.80	Sales past 5Y	-	Gross Margin	92.30%	52W Low	19.00%	ATR	0.63
Employees	67	Current Ratio	9.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.45	Volatility	3.36% 5.01%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	10.50%	Profit Margin	-	Rel Volume	0.30	Prev Close	13.07
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 BMO	Payout	-	Avg Volume	152.89K	Price	13.09
Recom	1.60	SMA20	-2.16%	SMA50	-0.83%	SMA200	-23.25%	Volume	8,166	Change	0.15%

Jan-11-22

Initiated

Jefferies

Buy

$45

Oct-01-21

Initiated

Cowen

Outperform

Sep-14-21

Initiated

Ladenburg Thalmann

Buy

$51

Sep-08-21

Initiated

Piper Sandler

Overweight

$45

Sep-01-22 08:00AM	Aadi Bioscience Announces Participation in Upcoming September Investor Conferences PR Newswire
Aug-10-22 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update PR Newswire
Aug-04-22 06:21AM	Is Aadi Bioscience, Inc. (NASDAQ:AADI) Popular Amongst Insiders? Simply Wall St.
Jul-28-22 08:30AM	Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update PR Newswire
Jun-23-22 08:00AM	Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes GlobeNewswire +6.00%
Jun-01-22 08:00AM	Aadi Bioscience to Present at the Jefferies Global Healthcare Conference GlobeNewswire
May-31-22 08:00AM	Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications GlobeNewswire
May-26-22 05:10PM	Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting GlobeNewswire +5.11%
May-18-22 07:00AM	Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference GlobeNewswire -7.91%
May-12-22 08:32AM	UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire +9.33%
07:00AM	Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update GlobeNewswire
May-09-22 08:00AM	Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders GlobeNewswire -10.81%
May-04-22 08:00AM	Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO from Centers for Medicare and Medicaid Services GlobeNewswire
Apr-28-22 05:07PM	Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 GlobeNewswire
Apr-18-22 08:00AM	Aadi Bioscience to Participate at the Jefferies Biotech on the Bay Summit GlobeNewswire -5.81%
Apr-08-22 01:09PM	Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) GlobeNewswire
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 Investopedia
Mar-31-22 02:45PM	Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes GlobeNewswire
Mar-17-22 07:00AM	Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update GlobeNewswire +8.40%
Mar-01-22 07:00AM	Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowens 42nd Annual Health Care Conference GlobeNewswire
Feb-25-22 04:41AM	Here's What Aadi Bioscience, Inc.'s (NASDAQ:AADI) Shareholder Ownership Structure Looks Like Simply Wall St.
Feb-23-22 07:00AM	Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa GlobeNewswire
Jan-04-22 04:30PM	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference GlobeNewswire
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... GuruFocus.com
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... GuruFocus.com
Nov-27-21 06:01AM	Companies Like Aadi Bioscience (NASDAQ:AADI) Are In A Position To Invest In Growth Simply Wall St.
06:01AM	Some Analysts Just Cut Their Aadi Bioscience, Inc. (NASDAQ:AADI) Estimates Simply Wall St.
Nov-23-21 04:22PM	Aadi Bioscience Pops And Then Tumbles After Snagging Its First FDA Approval Investor's Business Daily
06:00AM	Aadi Bioscience Announces FDA Approval of its First Product FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) GlobeNewswire
Nov-15-21 08:00AM	UPDATE Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) GlobeNewswire +7.31%
Nov-13-21 01:35PM	Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) GlobeNewswire
Nov-10-21 07:00AM	Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire -16.93%
Nov-09-21 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-01-21 04:05PM	Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer GlobeNewswire
Oct-25-21 08:00AM	Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer GlobeNewswire
Oct-22-21 08:00AM	Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology GlobeNewswire
Oct-19-21 05:22PM	Aadi Bioscience to Participate in H.C. Wainwrights 2nd Annual Precision Oncology Conference 2021 GlobeNewswire
Oct-06-21 08:00AM	Aadi Bioscience to Present New Preclinical Data on nab-Sirolimus (ABI-009) at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire
Sep-20-21 08:30AM	Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer GlobeNewswire
Sep-13-21 08:00AM	Aadi Bioscience Appoints Emma Reeve to its Board of Directors GlobeNewswire

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Desai Neil	See Remarks	Mar 18	Sale	20.07	3,550	71,234	1,915,543	Mar 22 05:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience